Vision 2030 Secretariat targets localized vaccine manufacturing to anchor Kenya's health infrastructure

The Director General of the Kenya Vision 2030 Delivery Secretariat, Kenneth Mwige, has issued a directive for the accelerated development of domestic vaccine manufacturing capabilities. Speaking at the 16th KEMRI Annual Scientific and Health (KASH) Conference at Safari Park Hotel, Mwige stated that strengthening local production is a national imperative anchored within the Fourth Medium Term Plan (MTP IV).

The strategy relies on a multi-agency framework where specific entities manage different stages of the value chain. BioVax Kenya is tasked with anchoring local production, while the Kenya Medical Research Institute (KEMRI) continues to lead research and innovation. This development comes as the government works to establish a self-reliant health manufacturing ecosystem that reduces dependence on external supply chains.

The infrastructure requirements for this transition involve the conversion and modernization of existing facilities into high-tech pharmaceutical hubs. Current works at the Embakasi site, managed by the Kenya BioVax Institute, include the transformation of former warehouse space into a specialized manufacturing facility. Phase 1A of the project, which covered essential utilities and waste management systems, has reached completion.

The next stage of construction and technical integration is expected to focus on the installation of fill-and-finish systems. These systems are critical for the final stages of vaccine production, allowing the facility to process imported drug substances into ready-to-use vials. Government timelines suggest that the first trial batches of locally manufactured vaccines could be released by the end of 2027 once the equipment is fully operational and validated.

Mwige emphasized that these projects are central to the broader goals of Universal Health Coverage. To support this, the Social Health Authority (SHA) has been identified as a key pillar for enabling sustainable financing, ensuring that the infrastructure remains viable through consistent demand and procurement.

On a continental scale, the push for Kenyan manufacturing aligns with the African Union goal of producing 60 percent of the continent’s vaccines locally by 2040. Achieving this will require significant investment in specialized engineering and the construction of facilities that meet World Health Organization (WHO) prequalification standards. 

The Director General noted that decisive action is now required to translate these policy frameworks into tangible outcomes. He called for stronger partnerships to facilitate technology transfer, particularly for advanced vaccine platforms like mRNA, which require specific cleanroom environments and cold-chain logistics infrastructure.

The KASH 2026 conference highlights a shift in Kenya’s medical infrastructure priorities, moving from primary care facility expansion toward high-end pharmaceutical manufacturing. By integrating regulatory systems with specialized production sites, the Secretariat aims to create a competitive industrial base that supports both national health needs and regional exports.